Pharmaceuticals company Ind-Swift Laboratories announced Q3FY26 results Total Revenue: Rs 177.06 crore against Rs 168.3 crore during Q2FY26, change 5%. EBITDA: Rs 9.11 crore against Rs 8.55 crore during Q2FY26, change 7%. EBITDA Margin: 5.95% for Q3FY26. PBT: Rs 17.61 crore against Rs 11.06 crore during Q2FY26, change 59%. PAT: Rs 10.74 crore against Rs 8.76 crore during Q2FY26, change 23%. PAT Margin: 6.07% for Q3FY26. N.R. Munjal Chairman & Whole Time Director, said: “Revenue remained stable for Q3FY26, while a reduction in raw material and employee benefit expenses drove a 6.60% increase in Operating EBITDA and an Operating EBITDA margin expansion of approximately 48 BPS. This improvement in operational efficiency, translated to a 22.60% rise in Net Profit (PAT) QoQ. Ind-Swift Laboratories Ltd has successfully completed a historic strategic reset through the Rs 1,650 crore divestment of its API & CRAMS business. This decisive action, combined with the merger of Ind-Swift Limited into ISLL, has transformed the company into a Net Debt Free entity with a unified operational structure. Currently, we operate as a Pure-Play Formulations Platform with a solid Revenue base of Rs 550 crore, driven primarily by high-quality exports. The restructuring has consolidated our capabilities across manufacturing, R&D; and distribution, positioning the entire organization for scalable, capitalefficient growth. Further we are accelerating execution across high-growth engines by strengthening CDMO visibility through the FY27 accretive Viatris partnership and expanding our Own-Brand footprint in UAE and Central Asia with 400+ registered products. Supported by high-margin segments like Ethical (76% GM), Own-Brand (51% GM) and CMO (42% GM) we are targeting sustained expansion to Double Revenue by FY29 while delivering consistent profitability.” Result PDF